Dr M Senthilraja

Verified email at gmail.com

Professor & Principal
Kasthooribha Gandhi Pharmacy College



                                   

https://researchid.co/rajdanish2k

CURRICULUM VITAE
Dr. M. SENTHILRAJA
M. Pharm, Ph.D, F.I.C,
Professor and Head
Department of Pharmaceutical Chemistry
J.K.K.Nattraja College of Pharmacy,
Komarapalayam -6381863,Namakkal Dt.
India
ContactAddress
Dr. M. Senthilraja, M.Pharm, Ph.D., F.I.C.,
C/o. Mr. V. Krishnappa
Door # 103, Shri Charan Nivasa,
# 30, Nagappa Street, Near Vinayaga Circle,
Palace Guttahalli
Bengaluru -560003
Email:rajdanish2k@gmail.com
Mobile: +919842295450
Personal Data
Father‟s Name: R. Manivannan
Date of Birth : 12.03.1974
Marital Status : Married
Languages Known
 English
 Kannada
Tamil
Malayalam
Computer Literacy
 Windows and Chem. Draw
 Power Point, Adobe Photoshop
 Molecular Modeling software
Professional Affiliations
Life Member in Indian Pharmaceutical Association (IPA)
Registered Pharmacist in Tamilnadu Pharmacy Council, Chennai
Associate Member in ISTE.
Life Member in InPharm (APTI)
Life Member in Fellowship in Chemists (FIC)
2
OBJECTIVE
To impart intrinsic knowledge of the subject in

EDUCATION

PhD In Pharmaceutical Sciences

RESEARCH INTERESTS

Drug design, New chemical entity, development of medicinal compounds, To develop drug .

FUTURE PROJECTS

Development of new drugs / molecules for the emerging diseases

Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries. These diseases predominantly affect the world’s poorest people. Currently available drugs are inadequate for the majority of these diseases, and there is an urgent need for new treatments. This Review discusses some of the challenges involved in developing new drugs to treat these diseases and highlights recent progress. While there have been notable successes, there is still a long way to go.


Applications Invited
Looking for Collaborators in this fields

Publications

RESEARCH PUBLICATIONS
1. Senthilraja. M. Application of Artificial Intelligence to Address Issues Related to Corono Virus, SLAS Technology Society for Laboratory Automation and Screening, 1(4), 2021, 1-4 (Impact Factor – 2.364) ISSN: 2472-6303 2472-6311 (web). https://doi.org/10.1177/247263032098381.
2. Senthilraja. M, Amudhavalli.K, Vijayabaskaran.M, Sambathkumar .R. N-Benzyl-Amino Fumaramates: A Novel Class of Antibacterial and Antioxidants. World Journal of Pharmacy & Pharmaceutical Sciences, 2021, 10(8),1704-1712. SJIF Impact Factor 7.632. [DOI : 10.20959/wjpps20218-19537 ], ISSN 2278 – 4357.
3. Senthilraja. M. Role of Pharmacists in the Management and Prevention of Pneumonia in Adults, Journal of Bio Innovation, 2(1), 2021, 12-15.(Impact Factor- 4.396). Cross Ref Prefix: 10.46344/JBINO.
4. M. Senthilraja, A Chemical Rationale of Drug Stability and Degradation- An Insightful Approach, International Journal of Advanced Community Medicine, Accepted for September 2021 issue.
5. Senthilraja Manivannan, Design, Synthesis and Evaluation of Chalcones as anti-microbial agent, Indian Journal of Forensic and Community Medicine 2020; 7(3):120–123. Doi: http://doi.org/10.18231/j.ijfcm.2020.026.
6. Senthilraja. M, Reverse Phase High Performance Liquid Chromatography and UV-Visible method for the simultaneous estimation of Gemifloxacin, Indian Journal of Pharmacy and Pharmacology, 2019; 6(2): 60-64. (Impact Factor: 1.15).DOI 10.18231/j.ijpp.
7. Senthilraja Manivannan.Substituted

RESEARCH OUTPUTS (PATENTS, SOFTWARE, PUBLICATIONS, PRODUCTS)

Principal Researcher of INDO-UKRAINE bilateral joint collaborative research project
from Department of Science & technology (DST), New Delhi, India with Danylo
Halytsky Lviv National Medical University, 79010, Lviv-10,Pekarska str, 69, Ukraine
from 2008 -2011.
Research group member of Danylo Halytsky Lviv National Medical University
Ukraine, 79010, Lviv-10, Pekarska str, 69.
Research group member of National University of Singapore, Singapore.
Research group member of Medicinal Chemistry Research Lab in MNR College of
Pharmacy, Sangaraddy, Telungana, India.

Industry, Institute, or Organisation Collaboration

Principal Researcher of INDO-UKRAINE bilateral joint collaborative research project
from Department of Science & technology (DST), New Delhi, India with Danylo
Halytsky Lviv National Medical University, 79010, Lviv-10,Pekarska str, 69, Ukraine
from 2008 -2011.
Research group member of Danylo Halytsky Lviv National Medical University
Ukraine, 79010, Lviv-10, Pekarska str, 69.
Research group member of National University of Singapore, Singapore.
Research group member of Medicinal Chemistry Research Lab in MNR College of
Pharmacy, Sangaraddy, Telungana, India.

INDUSTRY EXPERIENCE

10 years

STARTUP

Branded Medicine Selling
Generic Medicine Selling
Pharma Franchise
Institutional Sales i.e. supply to hospitals, colleges, departments etc
Over the Counter (OTC) Drugs Sale
Supply to Pharmacy Chains
Supply to Online Pharmacy
Pharmaceutical Product’s Export
Pharmaceutical Product’s Import
Active Pharmaceutical Ingredients and other raw material trading business
Medical Devices and Surgical Dressing business

SOCIAL, ECONOMIC, or ACADEMIC BENEFITS

f the pharmaceutical industry is a national asset, we should enact public policies to protect and strengthen it. Therefore, those of us in industry, medicine, and universities need to demonstrate effectively the dynamics of drug discovery something we may not have been well equipped to do up to this point.

This effort will be helped by university scholars who are working to develop a model for analyzing pharmaceutical risk versus return, as well as other related subjects. In addition, studies are being conducted at Merck to complement university efforts. At a minimum, I would suggest that any economic model for the industry should consider four important issues:

1.
We must reexamine the way research is treated. Should it be a profit and loss (P&L) expense or amortized as an asset? The answer is important because it will change a number of financial measurements, most notably return on assets.

2.
Our analyses must consider pricing, including costs of research and launch prices fair to the patient and to the innovating company.

3.
We need an adequate period of exclusivity for innovative products.

4.
We need to factor in the impact of inflation on the cost of doing business and of future research.

Economic analyses are under way in four broad areas: industry dynamics, risk/return trade-offs, research productivity and innovation, and the regulatory environment.